Few topics in women's health have generated as much confusion, and as many missed treatment opportunities, as menopausal hormone therapy (MHT). For over two decades, a single FDA black box warning shaped prescribing behavior, patient expectations, and clinical culture. But science has moved on; and now, so has the FDA. 

Here's what changed, why it matters, and what clinicians should take away. 

The WHI: How One Study Reshaped the Field 

In 2002, the Women's Health Initiative dropped a bombshell. The landmark trial reported increased risks of cardiovascular disease, stroke, thromboembolism, breast cancer, and dementia in women taking hormone therapy.^1,2 The reaction was swift: the FDA slapped broad black box warnings on estrogen and estrogen-progestogen products, and prescribing rates plummeted.^2,3

The problem? The warnings treated all patients as though their risks and experiences were identical. They made no distinction between: 

• A 52-year-old with debilitating hot flashes starting therapy at menopause onset 
• A 68-year-old with no symptoms initiating therapy 15 years post-menopause 
• Oral pills versus transdermal patches versus vaginal creams 

The result was a generation of women left untreated, suffering through vasomotor symptoms, accelerated bone loss, and diminished quality of life, because clinicians and patients alike were afraid of a warning label that didn'tapply to most of them.^2,3

What We Got Wrong (and What We've Learned Since) 

The WHI enrolled women with an average age of 63, often more than a decade past menopause.^1,4 We know now that's a critical detail, because the risks observed in that population don't translate neatly to younger, symptomatic women initiating therapy around the menopausal transition. 

Subsequent analyses have fundamentally reframed the conversation. The evidence now consistently shows that initiating hormone therapy before age 60 or within 10 years of menopause is associated with a markedly more favorable benefit-risk profile.^2,5 The concept of a “window of opportunity” has become a cornerstone of modern clinical guidelines. 

And what about the fear surrounding breast cancer? Long-term follow-up data tell a more nuanced story than the original headlines suggested. In the estrogen-alone arm, there was no increase in breast cancer mortality. In the combined estrogen-progestin arm, the increase in breast cancer mortality at 20-year follow-up was not statistically significant.¹

The lesson is clear: context matters. Timing matters. And broad, one-size-fits-all warnings were never well suited for decisions that require individualized risk assessment and care. 

November 2025: The Black Box Comes Off 

After 22 years, the FDA made a landmark decision by removing the boxed warning from menopausal hormone therapy products^1,3. This wasn't a casual regulatory update. It was an acknowledgment that the original warning had outlived its evidence base and was actively causing harm by discouraging appropriate use. 

The updated labeling reflects several key shifts:^1.5 

Formulation-specific risk language. Risks are now described based on route and formulation—oral versus transdermal versus vaginal—rather than lumped together as a class effect. Low-dose vaginal estrogen, for example, is recognized as having primarily local effects with minimal systemic risk.⁶

No more "lowest dose, shortest duration." That familiar refrain, once printed on every package insert, has been replaced by guidance that treatment duration should be driven by clinical judgment and individual patient needs, not by arbitrary limitation or automatic minimization.^1,5

Timing of initiation is now front and center. The FDA labeling now incorporates the window of opportunity concept, with guidance on optimal initiation within 10 years of menopause or before age 60.^1,2,5

These changes do not mean hormone therapy is without risk. They mean the conversation surrounding it should finally reflect the evidence more accurately.⁷ 

Risk communication needs an overhaul. Many patients still carry the fear instilled by two decades of black box warnings. Clinicians are now in a position to have more honest, evidence-based conversations by replacing vague warnings with contextualized, individualized risk assessments. 

The Bottom Line 

The removal of the FDA black box warning on menopausal hormone therapy is more than a labeling change, it's a course correction. For years, a well-intentioned but overly broad warning discouraged treatment for millions of women who could have benefited. The evidence now supports a more nuanced, individualized approach that accounts for timing, formulation, route, and patient-specific risk factors. 

For clinicians, the mandate is clear: move beyond the reflexive caution that defined the post-WHI era. Evaluate each patient individually, select the appropriate formulation and route of administration, and monitor thoughtfully over time. For appropriately selected patients, hormone therapy remains one of the most effective interventions for managing menopausal symptoms and supporting long-term health and quality of life. 

The black box is gone. It's time the clinical mindset caught up. 

References

1. Manson JE, Crandall CJ, Rossouw JE, et al. The Women’s Health Initiative Randomized Trials and Clinical Practice: A Review. JAMA. 2024;331(20):1748–1760. doi:10.1001/jama.2024.6542 
2. Bofill Rodriguez M, Yong LN, Mirkov S, Bekos C, Lethaby A, Farquhar C. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews. 2025;(11):CD004143. doi:10.1002/14651858.CD004143.pub6 (cochrane.org) 
3. Sriprasert I, Hodis HN, Mack WJ, et al. Elimination of the Black Box Warning on Menopausal Hormone Therapy. Obstet Gynecol. 2026;147(5):642-646. doi:10.1097/AOG.0000000000006226 
4. Buchanan LA, Calkins MW, Kirk JK. The Food and Drug Administration boxed warning on menopausal hormone therapy: history, impact, and a regulatory inflection point in women's health. Menopause. Published online April 14, 2026. doi:10.1097/GME.0000000000002793 
5. Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020;382(5):446-455. doi:10.1056/NEJMcp1714787. (ovid.com) 
6. Lambrinoudaki I, Armeni E, Milli N, Anagnostis P. Then and Now: What We Have Learned From the WHI. J Clin Endocrinol Metab. 2026;111(4):e974-e994. doi:10.1210/clinem/dgaf638 
7. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028